Trials / Sponsors / IO Biotech
IO Biotech
Industry · 4 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Melanoma, Squamous Cell Carcinoma of Head and Neck | Phase 2 | 2023-12-21 |
| Active Not Recruiting | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D1 Metastatic Melanoma, Unresectable Melanoma | Phase 3 | 2022-05-17 |
| Completed | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCH Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | 2022-04-11 |
| Completed | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC NSCLC | Phase 1 / Phase 2 | 2018-08-22 |